---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-266866"
form_type: "8-K"
ticker: "ACLX"
cik: "0001786205"
company_name: "Arcellx, Inc."
filed_at: "2025-11-05T23:59:59+00:00"
generated_at: "2026-05-17T00:21:31.220114+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Arcellx Q3 2025 net loss widens to $55.8M; collaboration revenue drops 81%

## Summary
- Cash, equivalents, and marketable securities of $576.0M as of Sep 30, 2025; expected to fund operations into 2028.
- Collaboration revenue fell to $4.9M from $26.0M YoY, driven by completion of anito-cel dosing in iMMagine-1 trial.
- R&D expenses decreased to $35.1M from $39.2M YoY; G&A expenses rose to $31.6M from $20.5M YoY on commercial readiness costs.
- Net loss was $55.8M compared to $25.9M in Q3 2024.

## SEC filing metadata
- accession: 0001193125-25-266866
- form_type: 8-K
- ticker: ACLX
- cik: 0001786205
- company_name: Arcellx, Inc.
- filed_at: 2025-11-05T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1786205/000119312525266866/0001193125-25-266866-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1786205/000119312525266866/aclx-20251105.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-266866
- JSON: https://secwatch.observer/filing/0001193125-25-266866.json
- Plain text: https://secwatch.observer/filing/0001193125-25-266866.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.